Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
- Mechanism
- Curator reviewed
Mechanism of action of girentuximab is antibody dependent cellular cytotoxicity (ADCC). As a monotherapy in metastatic renal cell carcinomas(RCC), girentuximab demonstrated minimal clinical activity with a 3% partial response rate and a median survival of 16 months. In vitro data suggest that the number of activated ADCC effector cells can be upregulated by low dose interleukin 2 (IL2) administered in a pulsatile fashion.
- Primary indication
- Investigated for use/treatment in gall bladder cancer and renal cell carcinoma.Curator reviewed
- Also known as
- Chimeric (human-murine) G250 IgG monoclonal antibody
- Code names
- CA9-SCAN CG250 · cG 250 · WX-G 250
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Girentuximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account